Scientific Advisory Board
Larry Kwak, M.D., Ph.D.
Chairman of
Scientific Advisory Board
Dr. Larry Kwak, M.D., Ph.D, is currently the Vice President and Cancer Center Associate Director, Translational Research & Developmental Therapeutics at City of Hope National Medical Center, as well as the chair of the Scientific Advisory Board at PeproMene Bio, Inc. Dr. Kwak served at the Biology Section, Experimental Transplantation and Immunology Branch, at the National Cancer Institute (NCI) for 12 years. His NCI laboratory is credited with the pioneering bench-to-clinic development of a therapeutic cancer vaccine for B-cell malignancies, which was recently reported as positive in a landmark national Phase III clinical trial.

From 2004-2014 Dr. Kwak served as Chairman of the Department of Lymphoma and Myeloma and Co-Director of the Center for Cancer Immunology Research at the University of Texas, M.D. Anderson Cancer Center in Houston, Texas, where he also held the Justin Distinguished Chair in Leukemia Research. Under his leadership, his department successfully captured extensive research support, including large team science grants, such as two SPORE grants in Lymphoma and Multiple Myeloma, respectively, from the NCI and a SCOR program project grant awarded by the Leukemia and Lymphoma Society.

A committed physician, scientist, and mentor, his vision is to assemble and lead research teams to integrate basic discoveries from academic laboratories with translational clinical development to first-in-human clinical trials of novel “homegrown” therapeutics, such as next generation cancer immunotherapies.

In 2010 Dr. Kwak was named to the TIME100, one of the world’s 100 most influential people named by TIME magazine, for his 20-year commitment to the science of cancer immunotherapy. In 2016, he was awarded the Ho-Am Prize in Medicine for his pioneering research in cancer immunotherapy.
Steven T. Rosen, M.D.
Scientific Advisory Board
Steven T. Rosen, M.D., FACP, FASCO, is the Provost, Chief Scientific Officer, and a director of the Comprehensive Cancer Center and the Beckman Research Institute, Irell & Manella Cancer Center Director’s Distinguished Chair for the City of Hope in Duarte, California. Following his graduation with distinction from Northwestern University Medical School’s Six-Year Honors Program in Chicago, Illinois, Dr Rosen completed his residency in internal medicine at Northwestern and a fellowship in medical oncology at the National Cancer Institute in Maryland. He served as the Director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine from 1989-2014.

Dr Rosen’s laboratory research focuses on experimental therapeutics and hematologic malignancies. He has received funding from the National Cancer Institute (NCI), American Cancer Society, Leukemia and Lymphoma Society (LLS), Multiple Myeloma Research Foundation, and Rising Tide Foundation. Dr Rosen has received numerous grant awards and contracts, and has published more than 400 scientific papers. He is editor-in-chief of Cancer Treatment and Research. Dr Rosen is the chair of the Medical Science Committee of the LLS and serves on its Board. He also serves on the Board of American Society of Clinical Oncology’s Conquer Cancer Foundation. Dr Rosen has been an advisor to more than two dozen NCI Comprehensive Cancer Centers.

He was the recipient of Northwestern University Medical School’s Alumni Achievement Award (1994), the Martin Luther King Humanitarian Award from Northwestern Memorial Hospital (1995), the Marv Samuel Award from the Chicago Baseball Cancer Charities (1996), recognition from the Woman’s Board of Northwestern Memorial Hospital for Compassionate Care (1996), and Israel Cancer Research Fund, Man of Distinction Award (2011), Lifetime Achievement Award (2015), and Best Doctors in Chicago and Los Angeles. Dr. Rosen is a member of the American Institute for Medical and Biological Engineering (AIMBE’s) College of Fellows (2017).

Bruce A. Beutler, M.D.
Scientific Advisory Board
Bruce Alan Beutler, M.D. is a Professor and Director of the Center for the Genetics of Host Defense at UT Southwestern Medical Center and the Raymond and Ellen Willie Distinguished Chair in Cancer Research. His prior involvements include Chairman of the Department of Genetics at The Scripps Research Institute and consultant for major biopharmaceutical companies such as Pfizer Inc.

Dr. Beutler is best known for receiving the Nobel Prize in Physiology or Medicine in 2011, and for his large-scale contributions to the advancement of both molecular and genetic studies of inflammation and innate immunity. He was the first to isolate and demonstrate the inflammatory potential of the mouse tumor necrosis factor-alpha (TNF), where he discovered its critical role in endotoxin-induced shock. He also has been elected a member of many honorary and learned societies, and presently holds four notable patents, including the invention of a drug that is highly effective in the treatment of rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis, and psoriasis.

Dr. Beutler received his B.A. in Biology from University of California, San Diego and his M.D. from the University of Chicago. He then did his residency at the Department of Neurology at UT Southwestern Medical Center and was a fellow at The Rockfeller University in New York.
Hong Qin, M.D., Ph.D.
Scientific Advisory Board
Dr. Hong Qin, M.D., Ph.D, former Instructor and Assistant Professor at the University of Texas MD Anderson Cancer Center, is a Scientific Advisory Board member of PeproMene Bio, Inc. and Associate Research Professor at the City of Hope Toni Stephenson Lymphoma Center.

Dr. Qin has been the principal investigator for major developments in the field of immuno-oncology, and most recently is researching the development of antibody therapy against immunosuppressive cells in blood cancer patients as well as the novel therapeutic humanized monoclonal antibodies against B cell activating factor receptors.

In 2013, he patented Myeloid-Derived Suppressor Cell-Specific Peptides for diagnostic and therapeutic use, and has been actively involved in the American Association for Cancer Research for over 10 years.

Dr. Qin received his Bachelors Degree from the University of Western Ontario in Anatomy Cell Biology, Medical Degree at the Shanghai Second Medical University, and Postdoctoral Training at the National Cancer Institute.